# üîç PREVIOUS LARGE COHORT VALIDATION - FINDINGS

**Date Found:** 2026-01-14  
**Status:** ‚úÖ **469-PATIENT VALIDATION ALREADY COMPLETE**

---

## üéØ KEY DISCOVERY

**A full validation run on 469 TCGA-OV patients was already completed in November 2024!**

**Source:** `.cursor/ayesha/RESISTANCE_PREDICTION_VALIDATED.md`  
**Date:** November 28, 2024  
**Status:** ‚úÖ VALIDATED for MAPK/NF1-based resistance prediction

---

## üìä VALIDATION RESULTS (469 Patients)

### **Pathway Separation Results**

| Signal | Sensitive | Resistant | Difference | Relative Risk |
|--------|-----------|-----------|------------|---------------|
| **NF1 mutations** | 4.5% | 16.1% | **+11.6%** | **3.5x** |
| **MAPK pathway** | 6.1% | 16.1% | **+10.1%** | **2.7x** |
| **NF1-mutant resistance rate** | - | 30.8% | vs 14.7% wildtype | **2.1x** |

### **What This Proves**

1. ‚úÖ **MAPK Pathway Validated**
   - Patients with MAPK pathway mutations: **2.7x higher resistance risk**
   - NF1 is the key driver gene

2. ‚úÖ **NF1 as Resistance Biomarker**
   - **3.5x enriched** in resistant patients
   - **30.8%** of NF1-mutant patients become resistant
   - vs **14.7%** of NF1-wildtype

3. ‚úÖ **Mechanism Vector Validated**
   - Current 7D vector: `[DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux]`
   - **MAPK dimension is VALIDATED** for resistance prediction

---

## üîó CONNECTION TO THERAPY FIT VALIDATION

### **What This Means for Current Plan**

**The pathway validation has ALREADY been done!**

- ‚úÖ **MAPK pathway**: 2.7x RR validated (plan target: ‚â•1.8x)
- ‚úÖ **NF1 mutations**: 3.5x enrichment validated
- ‚ö†Ô∏è **PI3K pathway**: Results not found in this document (need to check)

### **What Still Needs to Be Done**

1. **Therapy Fit Validation** (S/P/E framework)
   - Current run: Only 7 patients (debug limit)
   - **Still need:** Full cohort (300-350 patients) for S/P/E validation
   - **Different from pathway validation:** This validates drug efficacy prediction, not just pathway separation

2. **PI3K Pathway Results**
   - MAPK validated ‚úÖ
   - PI3K: Need to check validation output files

3. **S/P/E Framework Validation**
   - Pathway validation ‚â† Therapy Fit validation
   - Therapy Fit validates: `efficacy_score = 0.3√óS + 0.4√óP + 0.3√óE`
   - Pathway validation validates: Pathway mutations ‚Üí resistance

---

## üìÅ RELATED FILES

**Validation Scripts:**
- `scripts/validation/validate_mapk_ov_platinum.py` - MAPK validation
- `scripts/validation/validate_pi3k_ov_platinum.py` - PI3K validation

**Validation Outputs:**
- `scripts/validation/out/mapk_ov_platinum/report.json` - MAPK results
- `scripts/validation/out/pi3k_ov_platinum/report.json` - PI3K results

**Documentation:**
- `.cursor/ayesha/RESISTANCE_PREDICTION_VALIDATED.md` - Full validation report

---

## üéØ RECOMMENDATION

**The pathway separation validation is COMPLETE!**

**What's different:**
- **Pathway validation** (DONE): MAPK mutations ‚Üí resistance (2.7x RR)
- **Therapy Fit validation** (PENDING): S/P/E framework ‚Üí drug efficacy prediction

**Next steps:**
1. ‚úÖ **Acknowledge pathway validation is complete**
2. **Focus on Therapy Fit validation** (S/P/E framework)
3. **Run full cohort** (300-350 patients) for Therapy Fit
4. **Compare results** to pathway validation (should align)

---

**Key Insight:** The 469-patient validation was for **pathway separation** (resistance prediction), not **Therapy Fit** (drug efficacy prediction). Both are needed, but they validate different things!
